Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Everest OrganicsBOM:524790 +2.47%47 Gross Margin % is 43.73% as of Mar. 2026, which is 71% above its 10-year median of 25.60. GuruFocus rates BOM:524790 with a GF Score™ of 47/100 and a GF Value™ of ₹129.34 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 942 Drug Manufacturers companies, Everest Organics ranks worse than 69.85% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Everest Organics had a gross margin of 43.73% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Everest Organics Gross Margin % Related Terms
Everest Organics Gross Margin % Historical Data
* Premium members only.
The historical data trend for Everest Organics's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Everest Organics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Everest Organics Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Everest Organics's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Everest Organics's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Everest Organics (BOM:524790) has a Gross Margin % of 43.73% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Everest Organics and its competitors. This is 71% above median its historical median of 25.60. Over the past decade, Everest Organics' Gross Margin % has ranged from 15.81 to 38.21. According to the industry distribution chart, Everest Organics ranks #658 out of 942 companies in the Drug Manufacturers industry, placing it in the top 69.9%.
Is Everest Organics' Gross Margin % too high?
Everest Organics' current Gross Margin % of 43.73% is 71% above median its 10-year median of 25.60. Over the past 10 years, this metric has ranged from a low of 15.81 to a high of 38.21. The Drug Manufacturers industry median Gross Margin % is 48.50. Everest Organics' value of 43.73% is 9.8% below this industry median. Based on the distribution chart, Everest Organics ranks #658 out of 942 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Everest Organics has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Everest Organics' Gross Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Everest Organics ranks #658 out of 942 companies for Gross Margin %. This places Everest Organics in the lower half of its industry. The industry median Gross Margin % is 48.50. Everest Organics' value of 43.73% is 9.8% below this benchmark. Historically, Everest Organics' own Gross Margin % has ranged from 15.81 to 38.21 over the past decade. While the company's 10-year median is 25.60 vs. the industry median of 48.50, Everest Organics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.50, based on 942 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Everest Organics's current Gross Margin % of 43.73% is 9.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Everest Organics and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Everest Organics's current Gross Margin % is 43.73%, which is 71% above median its own 10-year median of 25.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Everest Organics stock overvalued right now?
Based on GuruFocus' analysis, Everest Organics (BOM:524790) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹129.34, compared to a current price of ₹307.15 — trading 137.5% above its estimated fair value. The current Gross Margin % is 43.73%, which is 71% above median its 10-year median of 25.60 and 9.8% below the Drug Manufacturers industry median of 48.50. Everest Organics' overall GF Score™ is 47/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Everest Organics (BOM:524790), the current Gross Margin % is 43.73% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Everest Organics (BOM:524790) Overvalued in 2026?
Based on GuruFocus' analysis, Everest Organics stock appears to be overvalued.
The current stock price of ₹307.15 is trading 137.5% above its estimated GF Value™ of ₹129.34.
GuruFocus considers Everest Organics to be Significantly Overvalued.
Key valuation signals for BOM:524790:
Gross Margin %: 43.73% (71% above median its 10-year median of 25.60)
GF Value™: ₹129.34 vs. price of ₹307.15 (137.5% above fair value)
Industry Position: 9.8% below the Drug Manufacturers median (#658 of 942)
No single metric tells the full story. See the BOM:524790 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Everest Organics Ltd is a pharmaceutical company. It is focused on manufacturing active pharmaceutical ingredients and intermediaries. The products offered by the company include Omeprazole, Ciprofloxacin, Dichloroflurobenzene, Naproxen, Benzimadizole, and others. The company operates in one primary business segment namely Active Pharmaceutical Ingredients (API) and their intermediaries. Geographically, it derives a majority of its revenue from India.
47GF Score
Get the complete analysis for BOM:524790
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524790 has been successfully added to your 
